Vident Advisory LLC Makes New $360,000 Investment in Axsome Therapeutics, Inc. $AXSM

Vident Advisory LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 3,083 shares of the company’s stock, valued at approximately $360,000.

A number of other large investors have also recently bought and sold shares of AXSM. Mutual of America Capital Management LLC boosted its stake in shares of Axsome Therapeutics by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock valued at $4,621,000 after purchasing an additional 136 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $25,000. GF Fund Management CO. LTD. boosted its stake in shares of Axsome Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,241 shares of the company’s stock valued at $145,000 after purchasing an additional 223 shares in the last quarter. Xponance Inc. boosted its stake in shares of Axsome Therapeutics by 8.7% in the 1st quarter. Xponance Inc. now owns 2,891 shares of the company’s stock valued at $337,000 after purchasing an additional 232 shares in the last quarter. Finally, Tocqueville Asset Management L.P. boosted its stake in shares of Axsome Therapeutics by 5.1% in the 1st quarter. Tocqueville Asset Management L.P. now owns 5,200 shares of the company’s stock valued at $606,000 after purchasing an additional 250 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark E. Saad sold 9,127 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $125.07, for a total transaction of $1,141,513.89. Following the completion of the sale, the director owned 10,002 shares of the company’s stock, valued at $1,250,950.14. This trade represents a 47.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Roger Jeffs sold 13,464 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $123.68, for a total transaction of $1,665,227.52. Following the sale, the director directly owned 57,510 shares of the company’s stock, valued at approximately $7,112,836.80. This trade represents a 18.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 100,299 shares of company stock valued at $11,766,554 in the last quarter. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $129.29 on Tuesday. The company has a market cap of $6.45 billion, a price-to-earnings ratio of -25.50 and a beta of 0.54. Axsome Therapeutics, Inc. has a 52 week low of $75.56 and a 52 week high of $139.13. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The firm has a 50 day moving average of $110.72 and a 200-day moving average of $110.72.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.08. The company had revenue of $150.04 million during the quarter, compared to the consensus estimate of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. On average, equities analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AXSM. Oppenheimer began coverage on shares of Axsome Therapeutics in a report on Tuesday, June 3rd. They issued an “outperform” rating and a $185.00 price objective for the company. Morgan Stanley began coverage on shares of Axsome Therapeutics in a report on Thursday, July 3rd. They issued an “overweight” rating and a $190.00 price objective for the company. Royal Bank Of Canada raised their price objective on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a report on Tuesday, August 5th. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. Finally, Wells Fargo & Company upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating and thirteen have given a Buy rating to the stock. According to MarketBeat, Axsome Therapeutics currently has an average rating of “Buy” and an average target price of $177.86.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.